Blood Pressure Management in Diabetic and Hypertensive Patients with Impaired Renal Function

Target Blood Pressure Recommendations

The American College of Cardiology recommends a blood pressure goal of less than 130/80 mmHg for adults with hypertension and chronic kidney disease (CKD) 1, 2
Patients with diabetes and hypertension are automatically assigned to the high-risk category for atherosclerotic cardiovascular disease (ASCVD), with the BP threshold for pharmacologic treatment at 130/80 mmHg or higher, according to the American College of Cardiology 3, 4
The American Journal of Kidney Diseases supports a BP target of less than 130/80 mmHg for patients with CKD, as most patients with CKD die of cardiovascular disease complications 3

The American College of Cardiology recommends treatment with an SBP goal of less than 130 mmHg for noninstitutionalized, ambulatory, community-dwelling adults aged 65 years or older with an average SBP of 130 mmHg or higher 3
The American College of Cardiology suggests careful titration of BP-lowering medications and close monitoring are especially important in older adults with a high burden of comorbidity 3
The American College of Cardiology recommends initiation of BP-lowering therapy, especially with 2 drugs, should be done with caution, with careful monitoring for adverse effects, including orthostatic hypotension, in elderly patients 4

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend a more aggressive systolic BP target of <120 mmHg for CKD patients, but this is considered an outlier among major international guidelines 5
The European Society of Cardiology guidelines recommend a systolic BP range of 130-139 mmHg for patients with CKD, and 120-129 mmHg for those with moderate-to-severe CKD with eGFR >30 mL/min/1.73 m² 6

The American Heart Association recommends treatment with an ACE inhibitor to slow kidney disease progression in patients with CKD (stage 3 or higher or stage 1 or 2 with albuminuria ≥300 mg/d) 1, 2
The American Heart Association suggests that if an ACE inhibitor is not tolerated, an angiotensin receptor blocker (ARB) may be used 1, 2

The American College of Cardiology recommends monthly evaluation of adherence and therapeutic response until control is achieved after initiation of drug therapy 3
The American Journal of Kidney Diseases suggests laboratory monitoring and clinic follow-up should occur every 3 to 6 months once target BP is achieved, depending on medications utilized and patient stability 2

The American Journal of Hypertension recommends avoiding excessive BP lowering in frail elderly patients due to increased risk of falls, fractures, acute kidney injury, and stroke 5
The American Journal of Kidney Diseases suggests multiple antihypertensive agents are usually required to reach target blood pressure in patients with diabetes and CKD 7
The American College of Cardiology recommends initiation of 2 antihypertensive agents from different classes for stage 2 hypertension (BP ≥160/100 mmHg) 3, 4
The American College of Cardiology suggests interventions to promote BP control, such as home BP monitoring, team-based care, and telehealth, are useful in improving BP control 3

The American College of Cardiology recommends a blood pressure goal of <130/80 mmHg for all adults with chronic kidney disease and hypertension, regardless of age, including young patients, due to the high cardiovascular risk inherent in CKD patients 8, 9
The vast majority of CKD patients have a 10-year ASCVD risk ≥10%, automatically placing them in the high-risk category requiring aggressive BP control 9

If the patient has significant proteinuria, the <130/80 mmHg target becomes even more critical for slowing kidney disease progression 9
The renal protective benefit of lower BP targets is most pronounced in the presence of significant proteinuria 10, 11

ACE inhibitors or ARBs should be the cornerstone of therapy in young patients with renal disease and hypertension, as they provide both BP control and direct renoprotection, particularly in proteinuric kidney disease 9, 12, 13, 14

Monitor BP, renal function, and electrolytes closely during the uptitration phase, and check basic metabolic panel within 2-4 weeks after initiating or titrating ACE inhibitors/ARBs 9
Implement home blood pressure monitoring to avoid excessive lowering and to confirm office readings, and schedule clinic follow-up every 6-8 weeks until target BP is safely achieved 9

Avoid lowering diastolic BP below 70 mmHg, as this increases cardiovascular risk, particularly coronary events, and monitor diastolic BP carefully when achieving systolic targets 8
Do not aggressively lower BP too rapidly; gradual reduction over weeks to months minimizes risk of acute kidney injury from hypoperfusion, and educate patients to hold or reduce antihypertensive medications during volume depletion 9

Young patients benefit most from aggressive BP control due to longer lifetime exposure to elevated pressures, and the actuarial benefit of BP reduction is greater in younger patients with more life-years to gain 10
The <130/80 mmHg target is particularly appropriate for young patients with CKD who face decades of cardiovascular risk 8, 9